IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications

Translational Oncology

Volumn 4, Issue 6, 2011, Pages 390-400

  Nguyen, Van ^a   Conyers, Jesse M ^a   Zhu, Dongqin ^a   Gibo, Denise M ^a   Dorsey, Jay F ^b   Debinski, Waldemar ^a   Mintz, Akiva ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; INTERLEUKIN 13 RECEPTOR ALPHA2; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WOUND HEALING;

EID: 82855172436     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11175     Document Type: Article

References (47)

1. Sathornsumetee S, Rich JN, and Reardon DA (2007). Diagnosis and treatment of high-grade astrocytoma. Neurol Clin 25, 1111-1139, x.
2. Davis FG, Freels S, Grutsch J, Barlas S, and Brem S (1998). Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88, 1-10.
3. Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, and Debinski W (2002). IL-13Rα2 is a glioma-restricted receptor for interleukin-13. Neoplasia 4, 388-399.
4. Debinski W and Gibo DM (2000). Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 6, 440-449.
5. Debinski W, Gibo DM, Hulet SW, Connor JR, and Gillespie GY (1999). Receptor for interleukin 13 is a marker and therapeutic target for human highgrade gliomas. Clin Cancer Res 5, 985-990.
6. Debinski W, Gibo DM, Slagle B, Powers SK, and Gillespie GY (1999). Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol 15, 481-486.
7. Debinski W, Slagle B, Gibo DM, Powers SK, and Gillespie GY (2000). Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 48, 103-111.
8. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, et al. (2010). Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci USA 107, 20021-20026.
9. Thompson JP, Nagy A, Schally AV, and Debinski W (2000). A small targeted anti-glioma chemotherapeutic based on mutated interleukin 13. Neuro Oncol 2, 298.
10. Zhou G, Ye GJ, Debinski W, and Roizman B (2002). Engineered herpes simplex virus 1 is dependent on IL13Rα2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA 99, 15124-15129.
11. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, and Jensen MC (2004). Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64, 9160-9166.
12. Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, and Connor JR (2006). Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther 5, 3162-3169.
13. Mintz A, Dorsey JF, Alavi A, and El-Deiry WS (2006). Retargeted cytokineimmunoglobulin fusion proteins to deliver radioisotopes for diagnosis, radioimmunotherapy and TRAIL sensitization of high grade astrocytoma and metastatic breast cancer. J Nucl Med 47(Suppl 1), 504.
14. Nguyen V, Hollingsworth C, Debinski W, and Mintz A (2010). A novel ligand delivery system that targets the IL13Rα2 tumor-restricted biomarker. J Nucl Med Meeting Abstracts 51, 58.
15. Debinski W, Gibo DM, Obiri NI, Kealiher A, and Puri RK (1998). Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol 16, 449-453.
16. Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, and Debinski W (2008). Protein-and DNA-based active immunotherapy targeting interleukin-13 receptor α2. Cancer Biother Radiopharm 23, 581-589.
17. Mintz A, Gibo DM, Madhankumar AB, and Debinski W (2003). Molecular targeting with recombinant cytotoxins of interleukin-13 receptor α2-expressing glioma. J Neurooncol 64, 117-123.
18. Debinski W, Obiri NI, Powers SK, Pastan I, and Puri RK (1995). Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1, 1253-1258.
19. Debinski W, Obiri NI, Pastan I, and Puri RK (1995). A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 270, 16775-16780.
20. Debinski W, Gibo DM, and Puri RK (1998). Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13. Int J Cancer 76, 547-551.
21. Kioi M, Husain SR, Croteau D, Kunwar S, and Puri RK (2006). Convectionenhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 5, 239-250.
22. Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, et al. (2006). Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20, E15.
23. Vogelbaum M, Sampson JH, Kunwar S, Chang S, Lang FF, Shaffrey M, Asher A, Croteau D, Parker K, Dul JL, et al. (2006). Phase I study final safety results: convection enhanced delivery of cintredekin besudotox (IL13-PE38QQR) followed by radiation therapy without and with temozolomide in newly diagnosed malignant glioma. Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO). Neuro Oncol 8(4), 453.
24. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, et al. (2007). Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25, 837-844.
25. Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, Rodriguez Ponce I, Pastan I, Puri RK, and Pedain C (2007). Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol 188, 703-709.
26. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, et al. (2007). Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61, 1031-1037, discussion 1037-1038.
27. Sampson JH, Archer G, Pedain C, Wembacher-Schroder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, et al. (2010). Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113, 301-309.
28. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, et al. (2010). Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12, 871-881.
29. Jarboe JS, Johnson KR, Choi Y, Lonser RR, and Park JK (2007). Expression of interleukin-13 receptor α2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67, 7983-7986.
30. Pandya H, Garg S, Gibo DM, Kridel S, and Debinski W (2009). Selection of a linear heptapeptide that binds interleukin 13 receptor α2 at a site distinct from the native ligand. Neuro Oncol 11, 597.
31. Debinski W, Dickinson P, and Gibo DM (2009). Novel monoclonal antibody 13R2. C3 against human and canine interleukin 13 receptor α-2. Neuro Oncol 11, 563-699.
32. Debinski W and Tatter SB (2009). Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 9, 1519-1527.
33. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, and Lassman AB (2009). Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73, 1200-1206.
34. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, and Baker SD (2007). Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6, 432-438.
35. Zelnak A (2010). Overcoming taxane and anthracycline resistance. Breast J 16, 309-312.
36. Atalay C, Deliloglu Gurhan I, Irkkan C, and Gunduz U (2006). Multidrug resistance in locally advanced breast cancer. Tumour Biol 27, 309-318.
37. Zhang L and Fang B (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12, 228-237.
38. Debinski W (2002). Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest 20, 801-809.
39. Wykosky J, Gibo DM, Stanton C, and Debinski W (2008). Interleukin-13 receptor α2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 14, 199-208.
40. Guerrero-Cazares H, Chaichana KL, and Quinones-Hinojosa A (2009). Neurosphere culture and human organotypic model to evaluate brain tumor stem cells. Methods Mol Biol 568, 73-83.
41. Chaichana K, Zamora-Berridi G, Camara-Quintana J, and Quinones-Hinojosa A (2006). Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. Stem Cells 24, 2851-2857.
42. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, and Weissman IL (2000). Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 97, 14720-14725.
43. Josiah DT, Zhu D, Dreher F, Olson J, McFadden G, and Caldas H (2010). Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther 18, 377-385.
44. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
45. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
46. Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, and Yu JS (2009). Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 27, 1734-1740.
47. Nash KT, Thompson JP, and Debinski W (2001). Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins. Crit Rev Oncol Hematol 39, 87-98.